AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2140965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent lower-body positive pressure (LBPP) for 10 min periods
Number of subjects: 8
Study 2140965 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lower-body positive pressure (LBPP) for 90 min
Number of subjects: 8
Study 6896406 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (xanthine oxidase inhibitor)
Number of subjects: 17
Study 6896406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29145788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) delivered via videoconferencing
Number of subjects: 251
Study 29145788 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) delivered in-person
Number of subjects: 251
Study 29555631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin (CD101) administered intravenously
Number of subjects: 0
Study 29555631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin (CD101)
Number of subjects: 0
Study 27401052 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit-finding intervention (gain-focused reappraisal strategies)
Number of subjects: 129
Study 27401052 — intervention group
Group type: COMPARATOR
Intervention: Simplified psychoeducation (lectures only)
Number of subjects: 129
Study 27401052 — intervention group
Group type: COMPARATOR
Intervention: Standard psychoeducation
Number of subjects: 129
Study 24738800 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh model in effect-site control mode with a ke0 of 0.6 min(‐1)
Number of subjects: 80
Study 24738800 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh model in effect-site control mode with a ke0 of 1.2 min(‐1)
Number of subjects: 80
Study 24738800 — intervention group
Group type: COMPARATOR
Intervention: Marsh model in blood concentration control
Number of subjects: 80
Study 24738800 — intervention group
Group type: EXPERIMENTAL
Intervention: Schnider model in effect-site control
Number of subjects: 80
Study 24159790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon (7.5 g) combined with antibacterial therapy
Number of subjects: 0
Study 24159790 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 20735821 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple anti-platelet therapy (cilostazol, aspirin, clopidogrel)
Number of subjects: 960
Study 20735821 — intervention group
Group type: COMPARATOR
Intervention: Dual anti-platelet therapy (aspirin and clopidogrel)
Number of subjects: 960
Study 20735821 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple anti-platelet therapy
Number of subjects: 960
Study 20735821 — intervention group
Group type: COMPARATOR
Intervention: Dual anti-platelet therapy
Number of subjects: 960
Study 18426639 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid daily
Number of subjects: 140
Study 18426639 — intervention group
Group type: COMPARATOR
Intervention: 5 mg folic acid weekly
Number of subjects: 140
Study 15832337 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure metrics from 16 exposed EDF employees
Number of subjects: 31
Study 15832337 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (15 individuals)
Number of subjects: 31
Study 12813158 — intervention group
Group type: EXPERIMENTAL
Intervention: Landing on an inverting surface (25 degrees of rotation)
Number of subjects: 0
Study 12813158 — intervention group
Group type: COMPARATOR
Intervention: Landing on a non-inverting surface
Number of subjects: 0
Study 10481354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-medicine system for asthma management
Number of subjects: 0
Study 10481354 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 8630564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-triggered ventilation (PTV) with peak inspiratory pressure of 10 cm H2O (PTV10)
Number of subjects: 6
Study 8630564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-triggered ventilation (PTV) with peak inspiratory pressure of 15 cm H2O (PTV15)
Number of subjects: 6
Study 8630564 — intervention group
Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 6
Study 8630564 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation with continuous positive airway pressure
Number of subjects: 6
Study 2026848 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG)
Number of subjects: 8
Study 7290755 — intervention group
Group type: EXPERIMENTAL
Intervention: GSR response to target stimuli
Number of subjects: 20
Study 7290755 — intervention group
Group type: COMPARATOR
Intervention: GSR response to nontarget stimuli
Number of subjects: 20
Study 31914291 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual reduction combined with vestibular rehabilitation exercises
Number of subjects: 186
Study 31914291 — intervention group
Group type: COMPARATOR
Intervention: Manual reduction
Number of subjects: 186
Study 27717222 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly (subcutaneous injections)
Number of subjects: 45
Study 27717222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25648901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (DP) using implanted electrodes
Number of subjects: 53
Study 25648901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacing (DP)
Number of subjects: 53
Study 25057189 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual short-term memory (vSTM) task
Number of subjects: 0
Study 25057189 — intervention group
Group type: EXPERIMENTAL
Intervention: Enumeration task
Number of subjects: 0
Study 25057189 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior parietal cortex (PPC) activation during both tasks
Number of subjects: 0
Study 25057189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis
Number of subjects: 0
Study 25057189 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational model of PPC using saliency map architecture
Number of subjects: 0
Study 22028071 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg of HyD per day
Number of subjects: 20
Study 22028071 — intervention group
Group type: COMPARATOR
Intervention: 20 µg (800 IU) of vitamin D(3) per day
Number of subjects: 20
Study 19687105 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group, interactive education about asthma
Number of subjects: 398
Study 19687105 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 398
Study 17296405 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral ethanol ablation of the prostate (15%, 25%, or 40% of prostate volume)
Number of subjects: 79
Study 15365075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory management
Number of subjects: 149
Study 15365075 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based management
Number of subjects: 149
Study 11715806 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH study intervention
Number of subjects: 20000
Study 9711797 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of recombinant hepatitis B vaccine (GenHevac B) intramuscularly (i.m.)
Number of subjects: 400
Study 9711797 — intervention group
Group type: COMPARATOR
Intervention: 2 micrograms of recombinant hepatitis B vaccine (GenHevac B) intradermally (ID)
Number of subjects: 400
Study 9711797 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms i.m. versus 2 micrograms ID
Number of subjects: 400
Study 9711797 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms ID
Number of subjects: 400
Study 7974084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-60 therapy followed by hormonotherapy after progression
Number of subjects: 48
Study 7974084 — intervention group
Group type: COMPARATOR
Intervention: Primary hormonotherapy with LH-RH analogue +/- Flutamide
Number of subjects: 48
Study 2566391 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms.kg‐1.min‐1 X 6 minutes, followed by 300 micrograms.kg‐1.min‐1 X 9 minutes)
Number of subjects: 60
Study 2566391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.8 microgram.kg‐1.min‐1 X 10 minutes)
Number of subjects: 60
Study 2566391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1094528 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine mouthrinse
Number of subjects: 10
Study 1094528 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 10
Study 31912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 134
Study 31912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET) for 12 weeks
Number of subjects: 134
Study 31912784 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 134
Study 31361018 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser enrichment
Number of subjects: 1200
Study 31361018 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1200
Study 28777749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (diet, exercise, cognitive training, and vascular risk management)
Number of subjects: 1260
Study 28777749 — intervention group
Group type: COMPARATOR
Intervention: General health advice (Control)
Number of subjects: 1260
Study 24973891 — intervention group
Group type: EXPERIMENTAL
Intervention: Wraparound care coordination
Number of subjects: 93
Study 24973891 — intervention group
Group type: COMPARATOR
Intervention: Intensive case management (ICM)
Number of subjects: 93
Study 24973891 — intervention group
Group type: EXPERIMENTAL
Intervention: Wraparound
Number of subjects: 93
Study 23957590 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5, Bifidobacterium Bb12) 1.3 × 10(10) CFU per capsule, two capsules twice daily for 6 months
Number of subjects: 131
Study 23957590 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two capsules twice daily for 6 months
Number of subjects: 131
Study 23957590 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and Placebo (both groups)
Number of subjects: 131
Study 21834970 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced pharmacist care (patient identification, assessment, education, close follow‐up, and prescribing/titration of antihypertensive medications)
Number of subjects: 0
Study 21834970 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18613226 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE) with identity link
Number of subjects: 0
Study 18613226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level method using proportions
Number of subjects: 0
Study 18613226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level method using log proportions
Number of subjects: 0
Study 18613226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level method using log odds
Number of subjects: 0
Study 16181005 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler
Number of subjects: 0
Study 16181005 — intervention group
Group type: EXPERIMENTAL
Intervention: Seretide Diskus
Number of subjects: 0
Study 16181005 — intervention group
Group type: COMPARATOR
Intervention: Both products
Number of subjects: 0
Study 14678587 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive adherence package (education programme, individualized planning, adherence aids)
Number of subjects: 43
Study 14678587 — intervention group
Group type: COMPARATOR
Intervention: Control (no adherence package)
Number of subjects: 43
Study 10655008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosenberg Self-Esteem Scale
Number of subjects: 143
Study 10655008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation
Number of subjects: 143
Study 8669654 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA fentanyl
Number of subjects: 45
Study 8669654 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA pethidine
Number of subjects: 45
Study 1734400 — intervention group
Group type: COMPARATOR
Intervention: Racemic epinephrine
Number of subjects: 31
Study 1734400 — intervention group
Group type: EXPERIMENTAL
Intervention: L-epinephrine
Number of subjects: 31
Study 6704838 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 well-baby visits
Number of subjects: 570
Study 6704838 — intervention group
Group type: COMPARATOR
Intervention: 5 well-baby visits
Number of subjects: 570
Study 30852650 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX
Number of subjects: 75
Study 30852650 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeza
Number of subjects: 75
Study 30852650 — intervention group
Group type: COMPARATOR
Intervention: VoLumen
Number of subjects: 75
Study 30852650 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 75
Study 29167974 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh placement
Number of subjects: 194
Study 29167974 — intervention group
Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 194
Study 27671175 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized left internal mammary artery (LIMA) harvesting
Number of subjects: 140
Study 27671175 — intervention group
Group type: COMPARATOR
Intervention: Pedicled left internal mammary artery (LIMA) harvesting
Number of subjects: 140
Study 24667153 — intervention group
Group type: EXPERIMENTAL
Intervention: 19% tax on sugar sweetened beverages (SSBs)
Number of subjects: 102
Study 24667153 — intervention group
Group type: COMPARATOR
Intervention: Regular prices (control condition)
Number of subjects: 102
Study 22500389 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Shenqi Dihuang Decoction (MSDD) plus basic treatment of Western medicine
Number of subjects: 118
Study 22500389 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment of Western medicine alone
Number of subjects: 118
Study 20599813 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal-excitatory PPC tDCS
Number of subjects: 0
Study 20599813 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 20599813 — intervention group
Group type: EXPERIMENTAL
Intervention: Right PPC tDCS
Number of subjects: 0
Study 20599813 — intervention group
Group type: EXPERIMENTAL
Intervention: Right parietal tDCS without training
Number of subjects: 0
Study 17290328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 0
Study 17290328 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (tyrosine kinase and angiogenesis inhibitors)
Number of subjects: 0
Study 12859305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 20
Study 12859305 — intervention group
Group type: COMPARATOR
Intervention: Abdominal wall lift
Number of subjects: 20
Study 10762680 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate cement
Number of subjects: 25
Study 10762680 — intervention group
Group type: COMPARATOR
Intervention: Hand-mixed conventional glass-ionomer cement
Number of subjects: 25
Study 10762680 — intervention group
Group type: COMPARATOR
Intervention: Capsulated conventional glass-ionomer cement
Number of subjects: 25
Study 10762680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement
Number of subjects: 25
Study 10762680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite cement
Number of subjects: 25
Study 10762680 — intervention group
Group type: EXPERIMENTAL
Intervention: All cements
Number of subjects: 25
Study 9172168 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk for NIDDM (defined by higher 2 h glucose and insulin values on oral glucose tolerance testing)
Number of subjects: 0
Study 9172168 — intervention group
Group type: COMPARATOR
Intervention: Patients with NIDDM
Number of subjects: 0
Study 8385741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg orally twice a day for nine months)
Number of subjects: 22
Study 8385741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing tablets)
Number of subjects: 22
Study 3957482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg three times daily for two weeks)
Number of subjects: 6
Study 3957482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31567306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation
Number of subjects: 0
Study 31567306 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30324580 — intervention group
Group type: EXPERIMENTAL
Intervention: AMDC‐USR (autologous muscle derived cells)
Number of subjects: 61
Study 30324580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27832689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 119
Study 27832689 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 119
Study 22945813 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (video, workbook, minimal counseling)
Number of subjects: 242
Study 22945813 — intervention group
Group type: COMPARATOR
Intervention: Control condition (brochure)
Number of subjects: 242
Study 22364383 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2601
Study 22364383 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention with drug-eluting stent (DES-PCI)
Number of subjects: 2601
Study 20484325 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct involvement by a community liaison/expert from the YMCA of Greater Indianapolis
Number of subjects: 10
Study 20484325 — intervention group
Group type: COMPARATOR
Intervention: Indirect involvement by a community liaison/expert from the YMCA of Greater Indianapolis
Number of subjects: 10
Study 17942181 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (30 min, 5 days/week for 3 months)
Number of subjects: 76
Study 17942181 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 76
Study 17942181 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 76
Study 15882173 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative combined chemoradiation (external‐beam radiotherapy to 45 Gy plus weekly cisplatin 50 mg/m2)
Number of subjects: 60
Study 15882173 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAIC) (cisplatin 50 mg/m2 and vincristin 1 mg/m2 every 7‐10 days for three courses)
Number of subjects: 60
Study 14624765 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (Genotropin, Pharmacia Corporation) for 6 months
Number of subjects: 17
Study 14624765 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 17
Study 10471419 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1415
Study 8704017 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT (medium chain triglycerides and long chain triglycerides) in a ratio of 1:1
Number of subjects: 0
Study 8704017 — intervention group
Group type: COMPARATOR
Intervention: LCT (long chain triglycerides)
Number of subjects: 0
Study 1877639 — intervention group
Group type: EXPERIMENTAL
Intervention: Toy Control Program
Number of subjects: 0
Study 1877639 — intervention group
Group type: COMPARATOR
Intervention: Toy activation only
Number of subjects: 0
Study 1877639 — intervention group
Group type: COMPARATOR
Intervention: Microcomputer programs with screen reinforcement only
Number of subjects: 0
Study 6283422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg median dose)
Number of subjects: 24
Study 6283422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30787078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 94
Study 30787078 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 94
Study 27652610 — intervention group
Group type: COMPARATOR
Intervention: Standard prasugrel therapy (control group)
Number of subjects: 2600
Study 27652610 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalating therapy (one-week prasugrel followed by one-week clopidogrel and PFT-guided maintenance therapy)
Number of subjects: 2600
Study 26100474 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery of the patella
Number of subjects: 50
Study 26100474 — intervention group
Group type: COMPARATOR
Intervention: No electrocautery of the patella (Control)
Number of subjects: 50
Study 24963659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training for smokers
Number of subjects: 18
Study 24963659 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral comparison group
Number of subjects: 18
Study 24963659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mindfulness and Cognitive-behavioral)
Number of subjects: 18
Study 24963659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training for smokers (abstinent at post-test)
Number of subjects: 18
Study 24963659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training for smokers (correlation with negative affect)
Number of subjects: 18
Study 22775317 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (Group 1, n = 8)
Number of subjects: 31
Study 22775317 — intervention group
Group type: EXPERIMENTAL
Intervention: glimepiride (Group 2, n = 7)
Number of subjects: 31
Study 22775317 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin or sitagliptin (Group 3, n = 16)
Number of subjects: 31
Study 22775317 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <7.3%
Number of subjects: 31
Study 22775317 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline HbA1c
Number of subjects: 31
Study 19848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Yupingfeng Mixture (YPF)
Number of subjects: 200
Study 19848211 — intervention group
Group type: COMPARATOR
Intervention: Transfer factor
Number of subjects: 200
Study 17224344 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy shakes
Number of subjects: 43
Study 17224344 — intervention group
Group type: COMPARATOR
Intervention: Casein shakes
Number of subjects: 43